GW 501516 (GW 1516 or GSK-516) is a drug that acts as a PPARδ modulator. GW 501516 activates and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound, as the combination has been shown to significantly increase exercise endurance in animal studies.

GW 501516 (also known as GW-501,516, GW 1516, GSK-516 and Endurobol) are PPARδ receptors. It activates the same pathway through exercise activation, including PPARδ. Has been investigated for potential treatments for obesity, diabetes, dyslipidemia and cardiovascular disease. When combined, GW 501516 has a synergistic effect: it has been shown that the combination significantly increases exercise tolerance in animal studies compared to the use of compounds alone.